Crenigacestat

Drug Profile

Crenigacestat

Alternative Names: LY-3039478

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Benzazepines; Small molecules
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute lymphoblastic leukaemia; Lymphoma
  • Phase I Cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma

Most Recent Events

  • 02 Jun 2017 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Preclinical trials in Hepatocellular carcinoma in USA (PO) before April 2017
  • 01 Apr 2017 Pharmacodynamics data from preclinical studies in Hepatocellular carcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top